Testing VRT106 in Adults With Returning or Growing Glioblastoma
Tests the drug VRT106 in adults with returning glioblastoma brain tumors.
Plain-language title generated from the registry record
Registry title: A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma
Key facts
- Where
- Beijing, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanning, Shenzhen, Xi’an, and Zhuhai, ChinaSee the 11 sites
- Phase
- Phase 1/2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07093814, who can take part
Where in China
- Sanbo Brain Hospital, Capital Medical UniversityBeijing, ChinaNot yet recruiting
- The Cancer Hospital Affiliated to Chongqing UniversityChongqing, ChinaNot yet recruiting
- Nanfang Hospital, Southern Medical UniversityGuangzhou, ChinaNot yet recruiting
- Sun Yat-sen University Cancer CenterGuangzhou, ChinaTaking people
- The Second Affiliated Hospital of Zhejiang University School of MedicineHangzhou, ChinaTaking people
- The First Affiliated Hospital of USTCHefei, ChinaNot yet recruiting
- Qilu Hospital of Shandong UniversityJinan, ChinaNot yet recruiting
- Guangxi Medical University Cancer HospitalNanning, ChinaTaking people
- Shenzhen Second People's HospitalShenzhen, ChinaTaking people
- Tangdu Hospital of Air Force Medical University of the PLAXi’an, ChinaNot yet recruiting
- The Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Guangzhou Virotech Pharmaceutical Co., Ltd.
- Trial code
- NCT07093814
- Record updated
- 29 October 2026
- Original description
This study is an open-label, single-arm Phase I/II clinical trial with the primary objective of evaluating the safety, tolerability, and efficacy of VRT106 in patients with recurrent/progressive glioblastoma.Read full original descriptionShow less
A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma
This study is an open-label, single-arm Phase I/II clinical trial with the primary objective of evaluating the safety, tolerability, and efficacy of VRT106 in patients with recurrent/progressive glioblastoma.
Inclusion: Subjects voluntarily participate in the clinical study; fully understand and be informed about the study and sign the ICF; and are willing to follow and have the ability to complete all trial procedures; Males and females are aged at 18-70 years (including borderline values) at the time of signing the ICF, male or female; Diagnosed with recurrent/progressive glioblastoma; Karnofsky Performance Status (KPS) score ≥60 within 28 days prior to the first administration of the study drug; An expected survival time of≥3 months; Have sufficient organ function; Female patients of childbearing potential must have a negative serum pregnancy test result within 7 days prior to the first use of the study drug (if a false-positive pregnancy test result is due to non-pregnancy factors such as illness, further testing via ultrasound or other methods is required, and the investigator must confirm the absence of pregnancy before enrollment); Subjects of childbearing potential (males and females) agree to use effective birth control with their partner from signing informed consent to at least 90 days after the last dose.
Exclusion: Previously received treatment with oncolytic viruses, gene therapy; Subject has received treatment with other unlisted clinical investigational drugs/devices within 4 weeks prior to the first dose of VRT106; Subject is known to have an allergic reaction to any of the components of VRT106; Patients with extracranial metastases; Patients who can't have a cranial MRI scan; Women who are breastfeeding.